Pioglitazone inhibits EGFR/MDM2 signaling-mediated PPARγ degradation

详细信息    查看全文

• 作者：Juanjuan Shi^a ; ^b ; ¹ ; Wenbo Zhang^c ; ¹ ; Mengli You^b ; Ying Xu^b ; Yongzhong Hou^b ; Jianhua Jin^a ; ^{jinjianhua19@126.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Pioglitazone ; PPARγ ; EGFR ; Ubiquitination ; Degradation
• 刊名：European Journal of Pharmacology
• 出版年：2016
• 出版时间：15 November 2016
• 年：2016
• 卷：791
• 期：Complete
• 页码：316-321
• 全文大小：1250 K

文摘

Aberrant activation of the epidermal growth factor receptor (EGFR) signaling is involved in many cancer events. Although peroxisome proliferator-activated receptor γ (PPARγ) has been implicated in inhibition of inflammation and cancer, EGFR/MDM2 signaling induces PPARγ phosphorylation and degradation. Here we found that cancer cells in response to EGF reduced PPARγ protein levels by inducing its phosphorylation, ubiquitination and degradation, but PPARγ agonist pioglitazone reversed this event. More importantly, pioglitazone increased cancer cell sensitivity to chemotherapy drugs. Therefore, our study revealed a novel mechanism that pioglitazone inhibited EGFR/MDM2-mediated cancer cell chemoresistance, which provides a novel strategy for cancer treatment.